IBAT inhibitors are being evaluated in clinical trials as an anticholestatic therapy (20) and have demonstrated clinical benefit in children and been approved for the treatment of progressive familial intrahepatic cholestasis and Alagille syndrome (21, 22). Here, SLC10A2 is linked to familial intrahepatic cholestasis.